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Resident bacteria are incriminated in the pathogenesis of experimental colitis and inflammatory bowel
diseases. We investigated the relative roles of various enteric bacteria populations in the induction and
perpetuation of experimental colitis. HLA-B27 transgenic rats received antibiotics (ciprofloxacin, metronida-
zole, or vancomycin-imipenem) in drinking water or water alone in either prevention or treatment protocols.
Mice were treated similarly with metronidazole or vancomycin-imipenem before or after receiving 5% dextran
sodium sulfate (DSS). Germfree transgenic rats were colonized with specific-pathogen-free enteric bacteria
grown overnight either in anaerobic or aerobic atmospheres. Nontransgenic rats colonized with anaerobic
bacteria served as negative controls. Although preventive metronidazole significantly attenuated colitis in
transgenic rats and DSS-treated mice, it had no therapeutic benefit once colitis was established. Ciprofloxacin
also partially prevented but did not treat colitis in B27 transgenic rats. In both animal models vancomycin-
imipenem most effectively prevented and treated colitis. Germfree transgenic rats reconstituted with enteric
bacteria grown under anaerobic conditions had more aggressive colitis than those associated with aerobic
bacteria. These results suggest that a subset of resident luminal bacteria induces colitis, but that a complex
interaction of commensal aerobic and anaerobic bacteria provides the constant antigenic drive for chronic
immune-mediated colonic inflammation.
Rapidly growing evidence supports the influence of normal
enteric bacteria on the pathogenic process of intestinal inflam-
mation and extraintestinal manifestations in experimental co-
litis and human inflammatory bowel diseases (IBD) (40–43).
Both spontaneous and induced inflammation in multiple
widely diverse rodent models have been associated with com-
mensal luminal bacteria (1, 11–13, 16, 22, 31, 44, 45, 52, 54).
The influence of resident bacteria on the induction and per-
petuation of spontaneous colitis and gastritis has been thor-
oughly studied in HLA-B27/b2-microglobulin transgenic (B27
TG) rats. Colitis, gastritis, and joint inflammation fail to de-
velop in B27 TG rats raised under germfree (sterile) conditions
(36, 49). Moreover, when transferred into a specific-pathogen-
free (SPF) environment, B27 TG rats universally develop im-
mune-mediated colitis and gastritis within 1 month of bacterial
colonization (36).
However, not all luminal bacteria have equal abilities to
cause inflammation. Antibiotics with narrow specificities, such
as metronidazole, which is selectively active against anaerobic
bacteria, are effective in Crohn’s colitis and ileocolitis (47) and
also attenuate chronic experimental intestinal inflammation
induced by indomethacin or carageenan in rats and guinea
pigs, respectively (32, 54). In addition, overgrowth of predom-
inantly anaerobic bacteria in bypassed small intestinal seg-
ments can lead to systemic inflammation. A jejunal self-filling
blind loop induces hepatobiliary inflammation resembling scle-
rosing cholangitis and reactivates quiescent arthritis in genet-
ically susceptible Lewis or Wistar rats (24, 25), and some pa-
tients undergoing surgical treatment for morbid obesity with
creation of bypassed jejunoileal segments develop arthritis and
hepatic and skin inflammation (8). In both examples, metro-
nidazole or broad-spectrum antibiotics with anaerobic speci-
ficities can reverse these systemic manifestations (15, 23, 25).
Creating a cecal self-filling blind loop in B27 TG rats alters the
cecal bacterial composition by significantly increasing luminal
concentrations of Bacteroides spp. and anaerobic bacteria rel-
ative to aerobic flora (37). This manipulation of cecal bacterial
composition markedly enhances cecal inflammation in these
rats, with submucosal inflammation and mucosal ulcers extend-
ing to the muscle layer (37). Furthermore, exclusion of the
cecum from the fecal stream decreases the total bacterial load
in the cecum and results in almost complete healing of cecal
inflammation and gastritis, although the concentration of gas-
tric bacteria does not change (37). The most convincing evi-
dence for selective induction of experimental gastrointestinal
inflammation with subsets of resident bacteria is provided by
reconstitution studies in gnotobiotic B27 TG rats. Previously
germfree B27 TG rats colonized with six different obligate and
facultative intestinal anaerobic bacteria including Bacteroides
vulgatus develop much more active colitis and gastritis than
littermates colonized with the same selected bacteria without
B. vulgatus (36). Of note, B27 TG rats colonized with a full
complement of SPF bacteria had more inflammation than the
B27 TG gnotobiotic rats colonized with the six bacterial species
including B. vulgatus. The importance of B. vulgatus in induc-
tion of colitis in this model was confirmed by monoassociation
studies, in which B. vulgatus but not Escherichia coli induced
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colitis equal to that induced by the group of six investigated
bacterial species (38). Interestingly, TG rats monoassociated
with B. vulgatus failed to develop gastritis, which was routinely
present in gnotobiotic rats colonized with the six different
bacterial strains (38) and in SPF B27 TG rats (36). However,
Onderdonk et al. (33) reported that high concentrations of E.
coli and Enterococcus species were associated with severe co-
litis in B27 TG rats. These results suggest that anaerobic bac-
teria, especially B. vulgatus, have a key role in initiating colitis
in B27 TG rats and that other bacterial species, although un-
able to initiate colitis independently, have an important role in
mediating inflammation in remote organs such as the stomach
and modulating the intensity of colitis.
Colitis induced by dextran sodium sulfate (DSS) in BALB/c
mice was first described in 1990 by Okayasu et al. (30) and is
now an established induced model of acute and chronic colitis.
Its association with enteric bacteria is well described (28, 30).
Okayasu et al. reported significant increases in the population
of members of the bacterial species Bacteroides, Enterobacter,
and Clostridium but decreases in Eubacterium spp. and Entero-
coccus spp. after acute DSS colitis (30). Bacteroides spp. were
identified as predominantly Bacteroides distasonis. Protective
effects of metronidazole and the combination of metronidazole
and ciprofloxacin in acute DSS colitis were demonstrated by
Ohkusa et al. (29) and Hans et al (19). However, Axelsson et
al. (6) have reported that acute DSS colitis can be induced
even in a germfree environment and is not significantly differ-
ent than intestinal inflammation in rodents maintained in a
conventional environment, suggesting a direct toxic effect of
DSS. In contrast, other investigators found significantly atten-
uated colitis in germfree mice treated with DSS (50). Several
groups have demonstrated that colitis occurs in SCID mice
treated for short periods with DSS (5, 14), suggesting that T
lymphocytes, B cells, and NK cells are not essential in the acute
phase of DSS colitis. Of interest, sulfasalazine treated colitis in
germfree DSS mice, even in the absence of bacteria, which are
essential to split sulfasalazine into active 5 amino salicylic acid
(5-ASA) (4).
To help determine which broad subsets of the complex res-
ident luminal bacterial population preferentially initiate and
perpetuate colitis in two distinctly different rodent models, we
administered several antibiotics with selective antimicrobial
activities to B27 TG rats and BALB/c mice with DSS-induced
colitis before and after the onset of intestinal inflammation. In
addition, we colonized germfree B27 TG rats with commensal
cecal bacteria grown under aerobic or anaerobic conditions.
B27 TG rats were selected because these rats develop well-
characterized chronic T-lymphocyte-mediated inflammation
when exposed to resident nonpathogenic enteric bacteria. The
DSS model was chosen to determine which commensal bacte-
ria mediate acute induced intestinal inflammation.
MATERIALS AND METHODS
Animals. Colonies of B27 TG rats and nontransgenic (NT) littermates on a
Fischer F344 background (18), originally obtained from Joel D. Taurog (South-
western Medical School, Dallas, Tex.), were housed and maintained in an SPF
environment and under germfree conditions (36). SPF female BALB/c mice
were obtained from Charles River, Sulzfeld, Germany, and housed under stan-
dard conditions.
Experimental design. B27 TG rats raised in an SPF environment were treated
with either antibiotics in drinking water or water alone (as controls) in preven-
tion and treatment protocols. NT rats housed under identical conditions served
as negative controls. Prevention (TG rats given water, n 5 8; TG rats given
ciprofloxacin, n 5 8; TG rats given metronidazole, n 5 9; TG rats given vanco-
mycin-imipenem, n 5 9; NT rats given water, n 5 9) started at 4 weeks of age,
soon after weaning and prior to the onset of colitis, which develops between 2
and 3 months of age in SPF conditions at our institution (36). Treatment (TG
rats given water, n 5 5; TG rats given ciprofloxacin, n 5 8; TG rats given
metronidazole, n 5 8; TG rats given vancomycin-imipenem, n 5 8; NT rats given
water, n 5 9) was begun at 3 months of age, when SPF B27 TG rats have
developed colitis by gross, histologic, and immunologic parameters (36). All rats
were killed at 4 months of age, after 1 month of antibiotic treatment and 3
months of prevention. At necropsy cecal tissues were taken for histology and
determination of interleukin-1b (IL-1b) protein, which has been validated as an
indicator of tissue inflammation (36–38). The antibiotics used in this experiment
were selected for their activities against various enteric bacterial populations.
Metronidazole (40 mg/kg of body weight/day) is selectively active against anaer-
obic bacteria, including gram-negative bacteria such as Bacteroides spp., whereas
ciprofloxacin (50 mg/kg/day) is most effective against enteric aerobic gram-
negative organisms, with an extended spectrum to anaerobic gram-positive bac-
teria. Imipenem (50 mg/kg/day), is a very-broad-spectrum antimicrobial drug
with efficacy against almost all gram-positive and gram-negative bacteria, includ-
ing anaerobes, except methicillin-resistant staphylococci, enterococci, and some
Pseudomonas spp. Vancomycin (50 mg/kg/day) was added to imipenem to cover
staphylococci and enterococci.
Acute colitis in BALB/c mice was established by adding 5% DSS (ICN Bio-
medicals Inc., Aurora, Ohio) to drinking water for 7 days (20, 30). DSS-treated
mice were also treated with either metronidazole (40 mg/kg/day) or vancomycin-
imipenem (50 mg/kg/day) in drinking water or with water alone as a positive
control. Water consumption was monitored on a daily basis. We were unable to
administer ciprofloxacin, since mice refused to drink water containing this agent.
Prevention started 3 days before DSS administration, and treatment began 2 days
after the onset of DSS feeding. All mice (n 5 5 for each group) were killed on
day 7. At necropsy cecal tissues were taken for histology.
B27 TG rats and NT littermates raised under germfree conditions (36) were
divided in two groups at the age of 2 months. Both groups were transferred into
separate isolators and colonized with different bacterial populations by oral and
anal gavage of 1 ml of culture medium containing the bacteria and placing 0.5 ml
on food pellets as previously described (36). One group of B27 TG rats (n 5 6)
received fecal bacteria from SPF TG rats; the bacteria were incubated overnight
in a thioglycolate broth in an anaerobic 5% CO2–10% H2–85% N2 atmosphere.
The second group of B27 TG rats (n 5 9) received fecal bacteria from the same
rat which were grown overnight in brain heart infusion broth under aerobic
conditions. NT rats (n 5 9) with fecal bacteria grown under anaerobic conditions
served as negative controls. Rats were killed 1 month after bacterial colonization.
Gross inflammatory scores. At necropsy the degree of thickening of the
mid-cecum of rats was blindly scored using a previously validated scale from 0 to
41 scale (36).
Histology. Tissues were prepared as previously described (36). A validated
histologic inflammatory score ranging from 0 to 41 was used for blinded eval-
uation of cecal inflammation in the B27 TG rats (36). This score was adapted to
mice with DSS-induced colitis.
Rat IL-1b enzyme-linked immunosorbent assay. We measured IL-1b protein
concentrations in homogenized cecal tissues by enzyme-linked immunosorbent
assay as previously described (37), using antibodies that were provided by S.
Poole, National Institute of Biological Standards and Controls, Hertfordshire,
United Kingdom. We previously have documented upregulation of IL-1 and
other proinflammatory cytokines produced by activated macrophages in SPF B27
TG rats (36) and correlated tissue IL-1b with histology scores and tissue myelo-
peroxidase (36–38).
Determination of luminal bacterial concentrations. The ceca of euthanized
non-B27 TG rats were removed, and 1 ml of cecal contents was taken immedi-
ately, weighed, and serially diluted in prereduced thioglycolate broth. From every
dilution 100 ml was plated on prereduced anaerobically sterilized agar plates in
an anaerobic 5% CO2–10% H2–85% N2 atmosphere. Aerobic culture was per-
formed using blood agar plates. Colonies were counted after 2 (aerobic culture)
and 6 (anaerobic culture) days of incubation at 37°C. Bacteroides spp. were
selectively grown on Bacteroides Bile Esculin agar under anaerobic conditions.
Morphology was checked by Gram staining. Total bacterial concentrations were
determined on serial dilutions with phase-contrast microscopy using a Neubauer
counting chamber. Identification of presumed Bacteroides spp. was performed by
standard procedures (46). Results were normalized for stool dry weights.
Statistical analysis. All data are expressed as the mean 6 standard error of the
mean (SEM). After testing for equal distribution, analysis of variance was used
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to test for differences between the groups. Gross and histologic inflammatory
scores, tissue IL-1b levels, and fecal bacterial concentrations with equal distri-
bution were compared to the control group (TG rats given water) using multiple-
comparison procedures (Bonferroni t test). Gross and histologic inflammatory
scores which did not pass the equal distribution test were analyzed using the
nonparametric Kruskal-Wallis one-way analysis of variance on ranks and Dunn’s
method for the multiple-comparison procedures. All tests were performed using
SigmaStat software from SSPS Inc. A P value of ,0.05 was considered statisti-
cally significant.
RESULTS
Antibiotics. To determine which broad classes of luminal
bacteria are responsible for initiation of colitis, 4-week-old SPF
B27 TG rats were given antibiotics with selective activities
prior to onset of colitis (preventive protocol). The same anti-
biotics were administered to 3-month-old B27 TG rats after
onset of colitis in a therapeutic protocol. The degree of colitis
was measured by blinded gross and histologic scores as well as
tissue IL-1b concentration, which is a validated marker of
macrophage activation and inflammation in this model (36–
38). Although preventive metronidazole significantly attenu-
ated colitis in B27 TG rats grossly (0.5 6 0.2, versus 1.6 6 0.3
for B27 TG rats given water; P , 0.05) and histologically (P ,
0.001) (Fig. 1), there was no benefit in treating with metroni-
dazole once colitis was established (gross gut score, 1.6 6 0.3
for metronidazole versus 1.9 6 0.6 water [not significant
{NS}]) (Fig. 1 and 2A and B). These results were confirmed by
cecal IL-1b (Fig. 3). Similarly, mice were treated with antibi-
otics 3 days before (prevention) or 2 days after (treatment)
onset of DSS administration. Metronidazole reduced the se-
verity of DSS-induced colitis when given prophylactically to
mice (P 5 0.01) (Fig. 4), but there was no statistically signifi-
cant therapeutic effect. The effect of ciprofloxacin on histologic
scores was similar to that of metronidazole (P , 0.05 in pre-
vention, NS in treatment) (Fig. 1), but it did not significantly
reduce the gross scores (prevention, 0.4 6 0.1 [NS]; treatment,
1.2 6 0.3 [NS]) or tissue IL-1b concentrations (Fig. 3) with
either protocol.
In both animal models broad-spectrum antibiotic therapy
with combined vancomycin-imipenem was effective in both
prevention (gross score, 0.2 6 0.1 [P , 0.05]; histologic scores,
P , 0.0001 [Fig. 1 and 4]; IL-1b, P , 0.01 [Fig. 3]) and
treatment of established colitis (gross score, 0.3 6 0.1 [P ,
0.01]; histologic scores, P , 0.0001 [Fig. 1, 2A and C, and 4];
IL-1b, P , 0.05 [Fig. 3]). However, even vancomycin-imi-
penem did not completely abrogate histologic inflammation in
the B27 TG rats (histologic score, P , 0.005 versus NT control
rats given water [Fig. 1]), although there was no difference in
IL-1b concentrations relative to NT control rats given water
(Fig. 3). In contrast, this broad-spectrum antibiotic combina-
tion almost completely blocked DSS-induced colitis (Fig. 4).
These results indicate that selective antibiotics can attenuate
the onset of colitis in two disparate models, but only broad-
spectrum treatment can reverse established disease. These
data suggest that both aerobic and anaerobic bacteria can
initiate inflammation but that a more complex group of bac-
teria is required to perpetuate disease.
Microbial assessments. We then measured total cecal con-
centrations of bacteria in antibiotic-treated versus water-
treated control rats as well as the relative concentrations of
anaerobic and aerobic subsets and Bacteroides species, which
have been implicated in the pathogenesis of colitis in B27 TG
rats (36, 38). Total cecal bacterial concentrations in the rats
were significantly reduced after 4 weeks of antibiotic treatment
in all therapeutic groups relative to the water-treated controls
(control, 2.7 3 1010 6 1.0 3 1010 CFU/g of stool; vancomycin-
imipenem, 2.0 3 108 6 0.8 3 108 CFU/g of stool [P , 0.025
versus control]; metronidazole, 1.9 3 109 6 0.6 3 109 CFU/g
of stool [P , 0.035 versus control]; ciprofloxacin, 3.9 3 109 6
0.5 3 109 CFU/g of stool [P , 0.045 versus control]) (Fig. 5)
but were lowest in the vancomycin-imipenem-treated animals
(P , 0.02 versus metronidazole and P , 0.0002 versus cipro-
floxacin) (Fig. 5), which had at least 1-log-unit-fewer organisms
than all other groups. Sequential evaluation of cecal bacterial
FIG. 1. Blinded histologic scores of the ceca from B27 TG treated with different antibiotics starting before (4 weeks of age, prevention protocol)
(h) and after (3 months of age, treatment protocol) (e) the onset of colitis. All rats were killed at 4 months of age. n 5 8 or 9 rats in each
group. p, P , 0.05 versus TG water controls. Cipro, ciprofloxacin; Metro, metronidazole; Vanco, vancomycin. Error bars indicate SEMs.
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concentrations revealed an initial 1,000-fold decrease of intes-
tinal flora after 3 weeks of therapy with vancomycin-imipenem
(5.4 3 107 CFU/g) with a subsequent increase in cecal concen-
trations to 1.3 3 109 CFU/g after 6 weeks, which was still
50-fold less than those in water-treated controls. The interval
increase in bacterial concentration between 3 and 6 weeks of
antibiotic administration was minimal in the metronidazole-
treated group and no increase was seen in the ciprofloxacin-
treated group, although the initial decrease was not nearly as
marked as with combination therapy (data not shown). At the
FIG. 2. (A) Photomicrograph of cecal inflammation in a 4-month-old SPF B27/b2-microglobulin TG rat treated with water alone. (B) A TG
rat treated with metronidazole after the onset of colitis (3 months of age) showed only slight reduction of cecal inflammation. (C) The cecum of
a TG rat treated with vancomycin-imipenem after the onset of colitis (3 months of age) revealed substantially less cecal inflammation. (D) Normal
cecum of a 4-month-old NT control rat treated with water alone.
FIG. 3. Tissue IL-1b protein concentrations of the ceca from B27 TG rats treated with different antibiotics starting before (4 weeks of age)
(h) and after (3 months of age) (e) the onset of colitis. p, P , 0.05 versus TG water. Cipro, ciprofloxacin; Metro, metronidazole; Vanco,
vancomycin. Error bars indicate SEMs.
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end of 8 weeks of antibiotic treatment cecal Bacteroides spp.
were absent in the metronidazole-and vancomycin-imipenem-
treated groups (with one exception in the vancomycin-imi-
penem-treated group) but were detected in all animals of the
ciprofloxacin-treated and control groups. The ratio of anaero-
bically to aerobically grown bacteria (reflecting the concentra-
tion of obligate anaerobic bacteria) compared with that in the
control group after three weeks of antibiotic therapy was 0.5 in
the vancomycin-imipenem-treated group, 0.1 in the metron-
idazole-treated group, and 1.5 in the ciprofloxacin-treated
group and did not change over the treatment period (Fig. 6),
suggesting a strong decrease of obligate anaerobic bacteria in
the metronidazole-treated group, a decrease of both aerobic
and anaerobic bacteria in the vancomycin-imipenem-treated
group (with slightly more effect on anaerobes than aerobes),
and a selective decrease of aerobic bacteria in the ciprofloxa-
cin-treated group. These results suggest that the decrease in
luminal bacterial concentrations correlates with the therapeu-
tic efficacy of antibiotics, that both aerobic and anaerobic bac-
terial populations are implicated in disease, and that while
Bacteroides spp. may be important in the pathogenesis of dis-
ease, clearly other bacterial strains have contributory roles.
FIG. 4. Blinded histologic scores of the ceca from BALB/c mice with DSS-induced colitis treated with different antibiotics starting 3 days before
or 2 days after the onset of DSS administration. The 5% DSS was continued for a total of 7 days. p, P , 0.05 versus water. h, Prevention; e,
treatment; ■, water control. Error bars indicate SEMs.
FIG. 5. Total bacterial concentrations in the cecal contents of NT rats treated with different antibiotics for 4 weeks, measured in a counting
chamber. p, P , 0.05 versus control; §, P , 0.05 versus ciprofloxacin (Cipro) and metronidazole (Metro). Vanco, vancomycin. Error bars indicate
SEMs.
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Reconstitution with enteric bacteria cultured under aerobic
versus anaerobic conditions. We then populated germfree B27
TG rats with aerobically and anaerobically cultivated enteric
bacteria to determine the relative abilities of these subsets to
induce experimental colitis. Rats were maintained in Trexler
isolators with sterile food and water for 1 month to prevent
colonization with other organisms. Both groups of rats had
similar concentrations of fecal bacteria (1012 CFU/g of stool),
which were comparable to levels in SPF rats. B27 TG germfree
rats colonized with a culture of SPF fecal flora incubated for 24
h in an anaerobic atmosphere developed more aggressive cecal
inflammation than littermates associated with aerobically cul-
tivated bacteria from the same source (histology scores, 2.3 6
0.2 for anaerobic atmosphere versus 1.4 6 0.1 for aerobic
atmosphere [P , 0.01]) (Fig. 7). However, B27 TG rats colo-
nized with the aerobic flora had significantly more inflamma-
tion than NT littermates colonized with anaerobes, which had
no evidence of colitis (0.3 6 0.1 [P , 0.0001]). These experi-
FIG. 6. Alteration of the ratio of anaerobic bacteria to aerobic bacteria by antibiotics compared to the ratio of anaerobic bacteria to aerobic
bacteria in the water control group ([anaerobes/aerobes with antibiotics]/[anaerobes/aerobes for water control]). Antibiotic treatment resulted in
an altered bacterial composition after 6 weeks. Compared with the water controls, vancomycin-imipenem reduced more anaerobes than aerobes
as demonstrated by the decreased ratio of anaerobes to aerobes to 0.5 of that of the water control group. This alteration of bacterial composition
was even exceeded by metronidazole, where the ratio of anaerobes to aerobes dropped to 1/10 of that of the water control group. In contrast
ciprofloxacin reduced predominantly aerobes as shown by the increase of the anaerobic/aerobic ratio to 1.5-fold that of the water control group.
FIG. 7. Blinded histologic scores of the ceca from germfree B27 TG rats colonized for 1 month with cultures of SPF cecal bacteria incubated
overnight under anaerobic or aerobic conditions. n 5 6 to 9 rats/group. p, P , 0.05 versus anaerobic; §, P , 0.05 versus aerobic. Error bars indicate
SEMs.
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ments indicate that both aerobic and anaerobic nonpathogenic
commensal bacteria can induce colitis in genetically suscepti-
ble rats, but the anaerobic population is more aggressive in this
model, despite equal fecal concentrations of the two bacterial
subsets.
DISCUSSION
Growing evidence in the past five years has supported the
crucial role of enteric bacteria in the pathogenesis of chronic
intestinal inflammation (41, 42). However, rodent models in-
dicate that not all bacteria have equal capabilities of inducing
gastrointestinal inflammation. Our present data further illus-
trate the complexities of bacterial composition in the patho-
genesis of experimental colitis in two different rodent models.
In the present study we used the DSS model as a prototype of
an acute inducible colitis and the B27 TG rat model as an
example of spontaneous, TH1 chronic immune-mediated gas-
trointestinal inflammation in a genetically engineered host (36,
48).
One major finding of the present study is the lack of thera-
peutic effects for antibiotics with narrow specificities. Metro-
nidazole was unable to treat inflammation once colitis was
established, although it was effective in both animal models in
a prevention protocol. On the other hand, the broad-spectrum
combination of vancomycin-imipenem was able to more effec-
tively prevent colitis as well as treat established disease. These
results are consistent with our previous observation that mono-
association of gnotobiotic B27 TG rats with B. vulgatus induced
colitis which was less aggressive than that present in SPF B27
TG rats (36, 38). Together these antibiotic and gnotobiotic
studies suggest a predominant role for Bacteroides spp. in ini-
tiating colitis in this model, with a synergistic effect of an
unknown number of other enteric bacteria in perpetuating and
mediating disease (37, 38). However, the observation that the
broad-spectrum combination of vancomycin-imipenem was
also significantly more effective than metronidazole in prevent-
ing colitis suggests initial proinflammatory capabilities from
bacterial species other than Bacteroides, since Bacteroides spp.
were undetectable in both metronidazole and vancomycin-imi-
penem treatment groups. The ability of certain aerobic bacte-
ria to initiate inflammation is further supported by the induc-
tion of mild colitis by colonization of germfree B27 TG rats
with aerobic bacteria and a modest protective effect of cipro-
floxacin in the present study. Videla et al. and Mourelle et al.
also showed that the vancomycin-imipenem combination was
superior to single antibiotics, including metronidazole, in ex-
perimental colitis induced by trinitrobenzene sulfonic acid (53)
and could prevent fibrosis in these rats with induced colonic
ulcers (27). Likewise, Madsen et al. (26) reported that the
combination of metronidazole and neomycin prevented and
treated colitis in IL-10-deficient mice and was superior to cip-
rofloxacin, which prevented the onset of colonic inflammation
but only partially reversed established colitis, while Hans et al.
(19) demonstrated that intraperitoneal metronidazole plus cip-
rofloxacin could improve acute but not chronic DSS-induced
colitis. Clinical trials further support the ability of metronida-
zole to prevent Crohn’s disease with modest therapeutic effects
as a single agent but improved efficacy in combination with
other antibiotics. Rutgeerts et al. (39) demonstrated that met-
ronidazole given after curative ileal resection for 3 months
significantly decreased postoperative recurrence of Crohn’s
disease for up to 1 year. In a therapeutic protocol monotherapy
with metronidazole significantly decreased the Crohn’s disease
activity index in patients with colitis and ileocolitis but had no
effect on patients with isolated ileal disease and did not lead to
a significant induction of remission (Crohn’s disease activity
index, ,150) (47). More recently, Prantera et al. (35) reported
that metronidazole in combination with ciprofloxacin was ef-
fective in the treatment of moderately active Crohn’s disease.
The preventive effect of ciprofloxacin in B27 TG rats, al-
though supported only by blinded histologic score and not by
IL-1b tissue concentration, was somewhat surprising in light of
our previous observations that B. vulgatus has a preferential
ability to induce colitis in this model (36, 38). Although others
report some effect of ciprofloxacin on Bacteroides spp. (34), in
our hands ciprofloxacin given in drinking water reduced total
intestinal bacterial concentrations less than 1 log unit and had
no effect on Bacteroides spp. Unfortunately we were unable to
test these findings in DSS-treated mice, since these mice re-
fused to drink water containing ciprofloxacin. Similarly, Mad-
sen et al. (26) showed only a modest decrease (1 log unit) in
mucosally adherent-invasive Bacteroides spp. following 8 weeks
of oral ciprofloxacin treatment in IL-102/2 mice, in contrast to
clearance of all detectable Bacteroides with neomycin-metron-
idazole administration. The lack of any effect of preventive
ciprofloxacin on the gross gut score and tissue IL-1b level in
our study and the preliminary results of Braat et al. (7), where
IL-102/2 mice treated either preventively or therapeutically
with the same dose of ciprofloxacin received no benefit, and of
Madsen et al. (26), where ciprofloxacin had only a modest
therapeutic benefit in established colitis in IL-102/2 mice, are
in contrast to our observed histologic findings. Similarly, re-
ports of the clinical effect of ciprofloxacin in IBD are somewhat
inconsistent. Turunen et al. described a concomitant role of
this antibiotic in preventing relapse of ulcerative colitis (51)
but no effect on Crohn’s disease using a similar protocol. How-
ever, recent reports by Colombel et al. (9) and preliminary data
by Arnold et al. (3) demonstrated beneficial therapeutic effects
of ciprofloxacin in mild to moderate active Crohn’s disease.
Gionchetti et al. have demonstrated efficacy of ciprofloxacin in
combination with a broad-spectrum nonabsorbable antibiotic,
rifaximin, in refractory pouchitis (17). These results suggest
that aerobic gram-negative bacteria contribute to intestinal
inflammation, which is supported by our observations of mod-
est induction of experimental colitis in B27 TG rats obtained
by aerobic cultures of cecal contents and by data from Onder-
donk and colleagues, who revealed a dramatic increase of E.
coli and Enterococcus spp. in cecal contents of HLA-B27 trans-
genic rats with severe chronic colitis (33).
The mechanism of action of metronidazole has been ques-
tioned in light of the possible direct immunomodulating capa-
bilities of this antibiotic in indomethacin-induced small bowel
inflammation (2, 10). In support of an antimicrobial role of
metronidazole in our experiments, we demonstrated a pro-
longed suppression of Bacteroides spp. with chronic adminis-
tration of metronidazole and with imipenem-vancomycin,
which were the agents which most effectively prevented colitis
in the B27 TG rats. Germfree B27 TG rats colonized with SPF
fecal bacterial flora grown overnight under anaerobic condi-
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tions developed active colitis, whereas population with aerobic
bacterial cultures devoid of all obligate anaerobic species, in-
cluding Bacteroides, produced only mild inflammation. While
these experiments do not exclude a possible synergistic immu-
nomodulatory effect of metronidazole, they indicate the im-
portance of obligate anaerobic bacteria in the pathogenesis of
colitis in this model.
Microbial assessment following antibiotic therapy revealed
interesting findings. Although vancomycin-imipenem predict-
ably suppressed bacterial counts after 3 weeks of administra-
tion, this was a transient effect with a 2-log-unit rebound in
total bacterial counts between 3 and 6 weeks, consistent with
the proliferation of resistant bacteria which partially repopu-
lated the colon despite continued antibiotic administration.
However, after 6 weeks of vancomycin-imipenem administra-
tion, total luminal bacterial counts remained 1 log unit less
than control levels. This delayed increase in bacterial concen-
trations was less evident with metronidazole treatment and was
absent with ciprofloxacin therapy. The discrepancy between
the prolonged therapeutic effect of vancomycin-imipenem ad-
ministration and increasing bacterial concentrations suggests
that this combination of antibiotics may have a lasting effect on
colitis by altering some components of the bacterial milieu in a
sustained fashion. This concept is supported by lack of detec-
tion of Bacteroides spp. even after 8 weeks of therapy with
vancomycin-imipenem despite a rebound in total bacterial
counts. Therapeutic effects of protracted administration of
vancomycin-imipenem may be prolonged because of the long-
term elimination of Bacteroides spp. and possibly other resi-
dent bacterial species, which may be sufficient to prevent re-
currence after induction of remission. Metronidazole, which
also permanently suppressed Bacteroides spp., was able to pre-
vent onset of colitis in B27 TG rats and to prevent relapse of
Crohn’s disease after a surgically induced remission (39). Clin-
ical studies have shown that chronic metronidazole therapy can
eliminate fecal Bacteroides for at least 6 months (21).
The present study convincingly reveals an important but
complex effect of luminal bacteria in the acute phase as well as
the chronic phase of experimental colitis. The present results
in conjunction with our previous observations strongly support
the following hypotheses (i) Normal luminal bacteria are re-
quired for development of chronic immune-mediated intesti-
nal inflammation. (ii) Commensal enteric bacterial species
have unequal proinflammatory capabilities, with some being
more aggressive than others. (iii) Various endogenous bacteria
have different roles in the inflammatory process. Some, includ-
ing Bacteroides spp. and other, yet-to-be identified species par-
tially suppressed by ciprofloxacin and more completely eliminated
by vancomycin-imipenem, preferentially initiate inflammation,
while another, perhaps larger spectrum of intestinal bacteria
perpetuate disease. (iv) An initial reduction of the total bac-
terial load with a broad-spectrum antibiotic combination alters
the bacterial composition with a lasting effect on intestinal
inflammation, although the total luminal concentration recov-
ers rapidly.
These findings have important clinical therapeutic implica-
tions and lay the foundation for clinical trials of broad-spec-
trum antibiotics or antibiotic combinations in human IBD. It
may be possible to treat active Crohn’s disease with a broad-
spectrum antibiotic combination until remission is achieved
and then switch to prophylactic therapy with metronidazole.
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